Therapeutic Specialty Rep: Launching Epinephrine Solution

Inizio Engage; Nicholasville (KY); Presencial; USD 125.000 - 150.000; Jornada completa

Ventajas ofrecidas por este puesto de trabajo

Bonus eligibility

Health care

Retirement benefits

Paid holidays

Vacation

Sick days

Descripción de la vacante

Aquestive Therapeutics is launching Anaphylm and seeks a Therapeutic Specialty Representative to build demand among healthcare providers. You will educate on payer strategies, drive adoption in your territory, and collaborate with district sales managers to execute the launch plan.

This role requires field-based clinical discussions, strong relationship-building, and the ability to navigate access barriers while meeting or exceeding territory targets. Travel about 30% is expected.

Formación

• Bachelor's degree.
• 3+ years in pharmaceutical, specialty, or B2B sales with targets.
• Deep understanding of payer coverage, prior authorization, and access barriers.
• Strong analytical skills translating data into actionable territory strategies.
• Willingness to travel overnight 30% for customer meetings and conferences.

Responsabilidades

• Design and execute territory business plans to identify high-potential accounts.
• Analyze prescribing patterns, payer landscapes, and competitive dynamics.
• Educate providers on Anaphylm's value and address objections.
• Drive formulary wins and in-office pull-through with providers.
• Maintain CRM with calls, sampling activity, and next steps.
• Ensure PDMA sampling compliance and AE reporting.

Descripción del empleo

Aquestive Therapeutics is launching Anaphylm and seeks a Therapeutic Specialty Representative to build demand among healthcare providers. You will educate on payer strategies, drive adoption in your territory, and collaborate with district sales managers to execute the launch plan.

This role requires field-based clinical discussions, strong relationship-building, and the ability to navigate access barriers while meeting or exceeding territory targets. Travel about 30% is expected.